Together, these findings demonstrate that CDX2-reinstatement therapy drives differentiation and apoptosis selectively in CDX2-low CRC models, both in vitro and in vivo, through PRKAB1-specific activation. This evidence concerns the gene CDX2 and colorectal carcinoma.